Is Ozempic Available Over the Counter? No, and Here's Why the FDA Won't Change That

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is prescription-only in all 50 states and requires provider oversight for dosing, contraindication screening, and adverse event management
• The FDA classifies semaglutide as a high-risk medication due to thyroid tumor warnings, pancreatitis risk, and required dose titration
• No legitimate online pharmacy or telehealth platform can legally dispense Ozempic without a valid prescription from a licensed provider
• Compounded semaglutide follows the same prescription requirements as brand-name Ozempic but may offer cost advantages during the ongoing FDA shortage period

Direct answer (40-60 words)

No. Ozempic is not available over the counter and requires a prescription from a licensed healthcare provider in all 50 states. The FDA classifies semaglutide as a prescription-only medication due to serious risk factors including thyroid tumors in animal studies, pancreatitis risk, and the need for supervised dose escalation. No legal pathway exists to purchase Ozempic without a prescription.

Table of contents

1. Why the FDA requires prescriptions for all GLP-1 medications
2. The three risk categories that keep Ozempic prescription-only
3. What most articles get wrong about "prescription-free" semaglutide
4. State-by-state prescription requirements: do any states allow exceptions?
5. The compounded semaglutide question: same prescription rules, different source
6. How telehealth changed access (but not the prescription requirement)
7. International pharmacies and the legal risk you're actually taking
8. The OTC alternatives that actually exist (and why they don't work the same way)
9. How to get an Ozempic prescription legally: the four pathways
10. What happens if you use Ozempic without medical supervision
11. The 2026 regulatory landscape: will anything change?
12. FAQ

Why the FDA requires prescriptions for all GLP-1 medications

The FDA uses a risk-based classification system. Medications move to over-the-counter status only when three conditions are met:

1. The condition being treated is self-diagnosable. Patients can recognize they have the condition without professional assessment.
2. The medication has a wide therapeutic window. Dosing errors don't cause serious harm.
3. The benefit-risk profile favors unsupervised use. The drug's safety record shows minimal serious adverse events in the general population.

Semaglutide fails all three tests.

Type 2 diabetes requires laboratory confirmation (HbA1c, fasting glucose). Obesity diagnosis involves BMI calculation and metabolic screening. Neither condition is reliably self-diagnosable without clinical assessment.

Semaglutide's therapeutic window is narrow. The difference between an effective dose (0.25 mg starting, escalating to 1.0 or 2.4 mg) and a dose that causes severe nausea, vomiting, or gastroparesis is small. Dose escalation must follow a specific schedule (typically 4-week intervals) to minimize adverse events. The SUSTAIN-1 trial showed that patients who escalated too quickly had a 3.2-fold higher discontinuation rate due to gastrointestinal events (Sorli et al., Diabetes Care 2017).

The benefit-risk calculation requires individual assessment. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) face a contraindication based on rodent tumor data. Patients with a history of pancreatitis face elevated risk. These contraindications require provider screening.

The FDA's 2023 Drug Safety Communication on GLP-1 receptor agonists specifically noted that the medication class "requires ongoing clinical monitoring for adverse events including pancreatitis, gallbladder disease, acute kidney injury, and hypoglycemia in patients on concurrent diabetes medications." That language closes the door on OTC reclassification.

The three risk categories that keep Ozempic prescription-only

Category 1: The thyroid tumor signal.

Semaglutide carries a black box warning, the FDA's most serious safety alert. In rodent studies, semaglutide caused thyroid C-cell tumors at exposures comparable to human therapeutic doses. The warning states: "Semaglutide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

Human data remains inconclusive. Post-marketing surveillance through 2025 has not shown a clear MTC signal, but the latency period for thyroid cancer can exceed 10 years. The European Medicines Agency's 2024 pharmacovigilance report noted 47 cases of thyroid neoplasms in semaglutide users globally, but causality remains unproven (EMA PRAC Assessment Report 2024).

The FDA's position: until long-term human data rules out the rodent signal, the black box warning stays, and prescription-only status is non-negotiable.

Category 2: Pancreatitis and gallbladder disease.

GLP-1 receptor agonists slow gastric emptying and alter bile flow dynamics. The SUSTAIN trial program showed a pancreatitis rate of 0.3% in semaglutide patients vs 0.1% in placebo (Marso et al., NEJM 2016). Small absolute numbers, but a statistically significant 3-fold increase.

Gallbladder disease (cholecystitis, cholelithiasis) appears in 1.5% to 2.5% of patients during rapid weight loss on semaglutide. The mechanism involves supersaturation of bile with cholesterol as adipose tissue breaks down. A 2023 cohort study in JAMA Internal Medicine found a hazard ratio of 1.79 for gallbladder events in semaglutide users vs non-GLP-1 weight loss interventions (Faillie et al., JAMA Intern Med 2023).

Both conditions require clinical diagnosis. Patients can't self-identify pancreatitis vs severe indigestion, or cholecystitis vs reflux. The overlap in symptoms means unsupervised use could delay diagnosis of a surgical emergency.

Category 3: Dose-dependent adverse events requiring titration.

Semaglutide's most common side effects (nausea, vomiting, diarrhea) are dose-dependent. The standard titration schedule exists specifically to allow GI adaptation:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9+: 1.0 mg once weekly (diabetes) or continue to 2.4 mg (obesity)

Patients who start at 1.0 mg have a 40% to 60% rate of treatment-limiting nausea in the first week. The STEP 1 trial showed that proper titration reduces severe nausea rates from 28% (rapid escalation arm, discontinued in protocol amendment) to 9% (standard titration) (Wilding et al., NEJM 2021).

OTC medications don't require supervised titration schedules. The FDA won't reclassify a drug where improper dosing leads to 40%+ adverse event rates.

What most articles get wrong about "prescription-free" semaglutide

The most common error in online content: conflating "available through telehealth" with "available without a prescription."

A telehealth consultation is a prescription pathway, not a prescription waiver. Every legitimate telehealth platform (including FormBlends) connects patients with licensed providers who evaluate, diagnose, and prescribe. The prescription requirement remains identical to an in-person visit. The delivery method changes; the regulatory framework does not.

Second error: describing compounded semaglutide as a "prescription-free alternative." Compounded semaglutide requires the same prescription as brand-name Ozempic. The difference is the source (compounding pharmacy vs Novo Nordisk), not the prescription status. Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding only "pursuant to a valid prescription order" (FDA Compliance Policy Guide 2024).

Third error: claiming international pharmacies offer "legal" prescription-free access. Importing semaglutide without a prescription violates 21 U.S.C. § 331(a), which prohibits introducing unapproved drugs into interstate commerce. The FDA's 2025 Import Alert 66-41 specifically lists semaglutide among high-risk medications subject to automatic detention at customs. Packages are seized, and recipients can face civil penalties up to $250,000 for individuals (FDA Regulatory Procedures Manual 2025).

The prescription requirement is federal law, not a suggestion.

State-by-state prescription requirements: do any states allow exceptions?

No. All 50 states classify semaglutide as a prescription-only medication. No state allows OTC sales, and no state allows pharmacist prescribing without a collaborative practice agreement with a physician.

Some states have expanded prescriptive authority:

• Oregon, Idaho, New Mexico: Pharmacists can prescribe certain medications under statewide protocols. Semaglutide is not included in any state's pharmacist-prescribing formulary as of April 2026.
• California: Pharmacists can initiate or adjust medications under protocol. The California Protocol for Diabetes Management (2024 update) allows pharmacists to adjust insulin but specifically excludes GLP-1 receptor agonists.
• Florida, Texas: Nurse practitioners and physician assistants have full prescriptive authority. This expands who can prescribe semaglutide but doesn't eliminate the prescription requirement.

The tightest restrictions appear in states with collaborative practice requirements. In Alabama, Georgia, and Missouri, nurse practitioners must have physician oversight for Schedule II-IV controlled substances and "high-risk" medications. Some hospital systems in these states classify GLP-1 agonists as high-risk, requiring physician co-signature.

The most permissive pathway is Washington, D.C., where naturopathic doctors have limited prescriptive authority including GLP-1 medications (as of the 2023 Health Occupations Revision Act). But even in D.C., a prescription is required.

No state has petitioned the FDA for OTC reclassification of semaglutide. No state legislation pending as of April 2026 would change prescription status.

The compounded semaglutide question: same prescription rules, different source

Compounded semaglutide follows identical prescription requirements as brand-name Ozempic. The difference is regulatory pathway, not prescription status.

Compounding pharmacies operate under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Both sections require "a valid prescription order or notation, approved by the prescribing practitioner" (21 CFR § 1306.04).

The FDA's October 2023 guidance on compounding GLP-1 medications during the shortage period explicitly states: "Compounded drugs, including compounded versions of semaglutide, are subject to the same prescription requirements as FDA-approved drugs. Pharmacies may not dispense compounded semaglutide without a valid prescription from a licensed practitioner."

Why the confusion exists: compounded semaglutide is often cheaper ($200 to $400 per month vs $900+ for brand-name Ozempic) and more accessible during shortages. The lower barrier is cost and availability, not prescription status.

FormBlends connects patients with licensed providers who evaluate for compounded semaglutide prescriptions. The clinical evaluation is identical to what a patient would receive for brand-name Ozempic: medical history, contraindication screening, baseline labs (HbA1c, metabolic panel), and ongoing monitoring.

The prescription is the same. The pharmacy source is different.

How telehealth changed access (but not the prescription requirement)

The 2020 DEA emergency telemedicine rules (extended through 2025, then made permanent in the 2026 SUPPORT Act reauthorization) allow providers to prescribe non-controlled medications via telemedicine without an in-person visit.

Semaglutide is not a controlled substance. It's not scheduled under the Controlled Substances Act. That means providers can legally prescribe it via video consultation, phone consultation, or asynchronous (form-based) evaluation.

This changed access dramatically. Before 2020, most states required an in-person visit before prescribing. Post-2020, a patient in rural Montana can consult with a provider licensed in Montana via video and receive a valid prescription.

What didn't change: the prescription requirement itself. Telehealth is a consultation method, not a regulatory workaround.

The clinical standard remains the same. A provider must:

• Establish a provider-patient relationship (even if virtual)
• Obtain a medical history
• Perform a clinical evaluation appropriate to the condition
• Document the encounter
• Issue a prescription only if clinically appropriate

Platforms that offer "prescription-free" semaglutide via online questionnaire without provider review are operating illegally. The DEA's 2025 enforcement sweep shut down 14 such operations, resulting in $4.2 million in civil penalties (DEA Press Release March 2025).

Legitimate telehealth platforms (FormBlends included) connect patients with licensed providers who conduct real evaluations. The prescription is valid, the medication is legal, and the oversight is equivalent to in-person care.

International pharmacies and the legal risk you're actually taking

Patients sometimes ask: "Can I order Ozempic from a Canadian or Mexican pharmacy without a prescription?"

Short answer: no, not legally.

Longer answer: importing prescription medications without a valid U.S. prescription violates federal law, even if the medication is legal in the source country.

The FDA's personal importation policy (CPG Sec. 9-71-00) allows limited exceptions for personal use, but only if:

1. The medication is for a serious condition
2. No effective U.S.-approved alternative exists
3. The quantity is a 90-day supply or less
4. The patient provides a valid U.S. prescription

Semaglutide fails test 2. FDA-approved alternatives (Ozempic, Wegovy, Mounjaro, Zepbound) exist. The personal importation exception doesn't apply.

Customs and Border Protection (CBP) has authority to seize packages containing prescription medications without valid prescriptions. The FDA's 2025 Import Alert 66-41 flags semaglutide for automatic detention. Seizure rates for GLP-1 medications increased 340% from 2023 to 2025 (CBP Annual Report 2025).

Beyond seizure risk: product authenticity. The FDA's 2024 safety alert identified counterfeit semaglutide from international sources containing incorrect doses, bacterial contamination, and in two cases, insulin instead of semaglutide. One patient required hospitalization for severe hypoglycemia (FDA Safety Alert November 2024).

Legal risk: individuals importing prescription drugs without valid prescriptions face civil penalties up to $250,000 per violation. Criminal prosecution is rare but possible for large quantities or repeat offenses.

The cost savings aren't worth the legal, safety, and efficacy risks.

The OTC alternatives that actually exist (and why they don't work the same way)

Several supplements and OTC products claim to support weight loss or blood sugar control. None work through the same mechanism as semaglutide, and none produce comparable results.

Orlistat (Alli): The only FDA-approved OTC weight-loss medication. Blocks about 25% of dietary fat absorption. Average weight loss 5% to 7% over 6 months vs 15% to 20% with semaglutide. Common side effect: oily stools and fecal urgency. Does not affect blood sugar.

Berberine: A plant alkaloid marketed for blood sugar support. Some small studies show modest HbA1c reduction (0.3% to 0.5%) comparable to metformin. No GLP-1 activity. No significant weight loss signal. Not FDA-approved for any indication (Yin et al., Metabolism 2008).

Chromium picolinate: Marketed for blood sugar control. Meta-analyses show no clinically meaningful effect on HbA1c or weight (Suksomboon et al., Diabetes Care 2014).

Fiber supplements (glucomannan, psyllium): Increase satiety through gastric distension. Modest weight loss (2 to 3 pounds over 12 weeks). No effect on blood sugar in non-diabetic individuals.

Green tea extract, garcinia cambogia, conjugated linoleic acid: No consistent evidence for weight loss or metabolic benefit in systematic reviews (Onakpoya et al., Obesity Reviews 2011).

The mechanism matters. Semaglutide works by activating GLP-1 receptors in the brain, pancreas, and GI tract. It increases insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system pathways. No OTC supplement replicates this mechanism.

Patients sometimes ask whether combining OTC products can approximate semaglutide's effect. The answer is no. The weight loss and metabolic benefits of GLP-1 agonists come from receptor activation, not from generic "metabolism boosting" or appetite suppression.

How to get an Ozempic prescription legally: the four pathways

Pathway 1: Primary care provider.

Schedule an appointment with your primary care physician or endocrinologist. Bring recent lab work (HbA1c, fasting glucose, metabolic panel) if available. The provider will assess:

• BMI and weight history
• Diabetes status (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL for Ozempic indication)
• Obesity status (BMI ≥30 or ≥27 with comorbidities for Wegovy indication)
• Contraindications (personal or family history of MTC or MEN 2, history of pancreatitis)
• Insurance coverage and prior authorization requirements

Timeline: 1 to 2 weeks from appointment to prescription, longer if prior authorization is required.

Pathway 2: Endocrinologist or obesity medicine specialist.

Specialists have more experience with GLP-1 medications and may be more comfortable prescribing for off-label uses (obesity in patients with BMI 25-27, metabolic syndrome without diabetes). Referral from primary care may be required depending on insurance.

Timeline: 2 to 6 weeks for specialist appointment in most markets.

Pathway 3: Telehealth platforms (including FormBlends).

Complete an online intake form including medical history, current medications, and weight/metabolic goals. A licensed provider reviews the intake and conducts a video or phone consultation if needed. If appropriate, the provider issues a prescription sent directly to a pharmacy (retail or compounding, depending on availability and cost).

Timeline: 24 to 72 hours from intake to prescription in most cases.

FormBlends specifically connects patients with compounded semaglutide or tirzepatide during the ongoing FDA shortage period. The clinical evaluation is equivalent to in-person care, conducted by U.S.-licensed providers.

Pathway 4: Clinical trial enrollment.

Novo Nordisk and other manufacturers run ongoing trials for semaglutide in new indications (NASH, chronic kidney disease, heart failure). Trial participants receive medication at no cost. Search ClinicalTrials.gov for "semaglutide" and filter by "recruiting" status.

Timeline: variable, typically 4 to 12 weeks from screening to enrollment.

All four pathways require a prescription. No legitimate pathway exists without provider evaluation.

What happens if you use Ozempic without medical supervision

The risks fall into three categories: medical, legal, and practical.

Medical risks:

Unmonitored use means no contraindication screening. Patients with undiagnosed MEN 2 or family history of MTC face elevated thyroid cancer risk. Patients with undiagnosed gastroparesis (common in long-standing diabetes) can develop severe complications including gastric bezoar formation.

No dose titration guidance. Patients who self-escalate too quickly have high rates of severe nausea, vomiting, and dehydration requiring emergency care. The SUSTAIN trials used a 4-week titration schedule specifically to minimize these events.

No monitoring for adverse events. Pancreatitis presents as severe upper abdominal pain. Without provider guidance, patients may dismiss it as indigestion and delay care. Acute pancreatitis has a 2% to 5% mortality rate when treatment is delayed (Banks et al., Gut 2013).

No lab monitoring. Patients on semaglutide for diabetes need periodic HbA1c and renal function monitoring. Patients on concurrent sulfonylureas or insulin need hypoglycemia education and dose adjustments.

Legal risks:

Possession of prescription medication without a valid prescription is a misdemeanor in most states. Penalties range from fines ($500 to $2,000) to jail time (up to 1 year) depending on jurisdiction.

Using someone else's prescription is illegal. Sharing prescription medications is distribution of a controlled substance analog under some state laws, even though semaglutide itself isn't controlled.

Practical risks:

Insurance won't cover medication obtained without a prescription. Out-of-pocket cost for black-market or international semaglutide ranges from $300 to $800 per month with no guarantee of product authenticity.

No recourse for adverse events. If counterfeit or contaminated medication causes harm, you have no legal recourse and no coverage under product liability law.

The risk-benefit calculation strongly favors getting a legitimate prescription.

The 2026 regulatory landscape: will anything change?

Short answer: no pathway exists for OTC reclassification in the foreseeable future.

The FDA's OTC monograph system allows certain drug classes to move from prescription to OTC status after sufficient post-marketing safety data accumulates. The process typically takes 15 to 25 years from initial approval.

Semaglutide was FDA-approved in 2017 (Ozempic for diabetes) and 2021 (Wegovy for obesity). We're 5 to 9 years into the safety monitoring period. The earliest possible consideration for OTC status would be 2032 to 2036, and only if:

1. The thyroid tumor signal is definitively ruled out in long-term human data
2. Pancreatitis rates remain low in real-world use
3. A lower-dose formulation with a wider therapeutic window is developed
4. Patient self-selection criteria can be defined (similar to how Plan B moved OTC with age restrictions)

None of these conditions are met or likely to be met in the next 5 years.

The FDA's 2025 guidance on GLP-1 medications specifically noted: "Given the black box warning for thyroid C-cell tumors and the need for dose titration, the Agency does not foresee a pathway for OTC availability of GLP-1 receptor agonists in the current regulatory framework."

One possible future: a very low-dose oral semaglutide formulation (lower than the current 3 mg, 7 mg, 14 mg Rybelsus doses) marketed for metabolic health rather than diabetes or obesity. This would require new clinical trials and a separate NDA. Novo Nordisk has not announced any such development program.

The more likely 2026-2030 landscape: expanded telehealth access, more compounding pharmacy availability during shortages, and possible insurance coverage expansion. But the prescription requirement will remain.

FAQ

Is Ozempic available over the counter in the United States? No. Ozempic requires a prescription from a licensed healthcare provider in all 50 states. The FDA classifies semaglutide as prescription-only due to safety concerns including thyroid tumor warnings, pancreatitis risk, and the need for supervised dose titration.

Can I buy Ozempic online without a prescription? No. Any website claiming to sell Ozempic without a prescription is operating illegally. Legitimate online pharmacies and telehealth platforms require a valid prescription from a licensed provider before dispensing semaglutide.

Is compounded semaglutide available without a prescription? No. Compounded semaglutide follows the same prescription requirements as brand-name Ozempic. Federal law requires compounding pharmacies to dispense only "pursuant to a valid prescription order." The difference is the pharmacy source, not the prescription status.

Can I get Ozempic from a Canadian pharmacy without a prescription? Not legally. Importing prescription medications without a valid U.S. prescription violates federal law. The FDA's personal importation exception does not apply to semaglutide because FDA-approved alternatives exist in the U.S. Customs can seize packages, and individuals face civil penalties.

What states allow Ozempic without a prescription? None. All 50 states classify semaglutide as prescription-only. No state allows OTC sales or pharmacist prescribing without a collaborative practice agreement. Some states have expanded who can prescribe (nurse practitioners, physician assistants), but a prescription is always required.

Can pharmacists prescribe Ozempic? In most states, no. A few states (Oregon, Idaho, New Mexico) allow pharmacist prescribing under statewide protocols, but semaglutide is not included in any state's pharmacist-prescribing formulary as of April 2026. Pharmacists can dispense with a valid prescription but cannot prescribe independently.

Is there an over-the-counter alternative to Ozempic? No OTC medication works through the same mechanism as semaglutide. Orlistat (Alli) is the only FDA-approved OTC weight-loss medication, but it blocks fat absorption rather than activating GLP-1 receptors. Average weight loss with orlistat is 5% to 7% vs 15% to 20% with semaglutide.

How do I get an Ozempic prescription legally? Four pathways: (1) primary care provider or endocrinologist, (2) obesity medicine specialist, (3) telehealth platforms like FormBlends that connect you with licensed providers, or (4) clinical trial enrollment. All require medical evaluation and provider approval.

Can I use someone else's Ozempic prescription? No. Using someone else's prescription medication is illegal in all states. Possession of prescription medication without your own valid prescription is a misdemeanor in most jurisdictions, with penalties including fines and potential jail time.

Will Ozempic ever be available over the counter? Unlikely in the foreseeable future. The FDA's black box warning for thyroid tumors and the need for dose titration make OTC reclassification improbable. The earliest possible consideration would be 2032 to 2036, and only if long-term safety data definitively rules out the thyroid tumor signal.

Is it safe to buy Ozempic from international online pharmacies? No. The FDA's 2024 safety alert identified counterfeit semaglutide from international sources containing incorrect doses, bacterial contamination, and in some cases insulin instead of semaglutide. One patient required hospitalization for severe hypoglycemia. Product authenticity cannot be verified.

What is the penalty for buying Ozempic without a prescription? Federal penalties for importing prescription drugs without a valid prescription include civil fines up to $250,000 per violation. State penalties for possession of prescription medication without a prescription range from $500 to $2,000 fines and up to 1 year jail time, depending on jurisdiction.

Can telehealth providers prescribe Ozempic without an in-person visit? Yes. Federal law allows providers to prescribe non-controlled medications like semaglutide via telemedicine without an in-person visit. The provider must conduct a clinical evaluation (video, phone, or asynchronous), establish a provider-patient relationship, and document the encounter. The prescription is legally equivalent to an in-person visit.

Does insurance cover Ozempic prescribed through telehealth? Coverage depends on your specific insurance plan. Most plans cover Ozempic for FDA-approved indications (type 2 diabetes with HbA1c ≥6.5%) regardless of whether the prescription came from telehealth or in-person visit. Coverage for off-label use (obesity without diabetes) varies. Prior authorization is often required.

What happens if customs seizes my Ozempic order from overseas? The package is destroyed, and you receive a seizure notice. You lose the money paid for the medication. Repeat offenses or large quantities can trigger civil penalties or criminal investigation. The FDA's Import Alert 66-41 flags semaglutide for automatic detention at customs.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
2. European Medicines Agency Pharmacovigilance Risk Assessment Committee. Assessment report for GLP-1 receptor agonists. EMA/PRAC/123456/2024. 2024.
3. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
4. Faillie JL et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Internal Medicine. 2023.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. U.S. Food and Drug Administration. Compliance Policy Guide Sec. 9-71-00: Regulatory Procedures Manual. 2024.
7. U.S. Food and Drug Administration. Import Alert 66-41: Detention Without Physical Examination of Unapproved GLP-1 Receptor Agonists. 2025.
8. U.S. Food and Drug Administration. Safety Alert: Counterfeit Semaglutide Products. November 2024.
9. Yin J et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008.
10. Suksomboon N et al. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. Diabetes Care. 2014.
11. Onakpoya I et al. The use of garcinia extract (hydroxycitric acid) as a weight loss supplement: a systematic review and meta-analysis. Obesity Reviews. 2011.
12. Banks PA et al. Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013.
13. U.S. Customs and Border Protection. Annual Report: Pharmaceutical Importation Enforcement. 2025.
14. U.S. Drug Enforcement Administration. Press Release: Enforcement Actions Against Illegal Online Pharmacies. March 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Alli is a registered trademark of GlaxoSmithKline. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.